Johanna Mercier

Johanna Mercier

DirectoratGilead Sciences· In proxies 2019–2025

Pay in FY2025+8% from the year before · Gilead Sciences stock +32.9% the same year

Johanna Mercier was paid $9.3M in FY2025 (Dec), up 8%. Gilead Sciences stock rose 32.9% that year.

Pay$100 in the stock at the end of FY18 → $231
Pay is from the Summary Compensation Table of each Gilead Sciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Neurocrine BiosciencesPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Gilead SciencesPublic company · 7 yr
    • Chief Commercial and Corporate Affairs Officer2019 – Present · 7 yrStock in role +210%
  3. Arcus Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Neurocrine BiosciencesDirector · 4 yr on the boardIndependentCorporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?